HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies

Overview

Journal J Pers Med

Date 2020 Feb 27

PMID 32098203

Citations 5

Authors

Antonio Ieni

Roberta Cardia

Cristina Pizzimenti

Pio Zeppa

Giovanni Tuccari

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor receptor-2 (HER2)-expression gastro-oesophageal adenocarcinomas (GEA) gained interest as an important target for therapy with trastuzumab. In the current review, we focused the current knowledge on HER2 status in dysplastic and neoplastic gastric conditions, analyzing the methodological procedures to identify HER2 expression/amplification, as well as the proposed scoring recommendations. One of the most relevant questions to evaluate the useful impact of HER2 status on therapeutic choice in GEAs is represented by the significant heterogeneity of HER2 protein and gene expression that may affect the targeted treatment selection. Future development of biotechnology will continue to evolve in order to offer more powerful detection systems for the assessment of HER2 status. Finally, liquid biopsy as well as mutation/amplification of several additional genes may furnish an early detection of secondary HER2 resistance mechanisms in GEAs with a better monitoring of the treatment response.

Citing Articles

Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target.

Rogers J, Yamashita K, Sewastjanow-Silva M, Trail A, Waters R, Ajani J Cancers (Basel). 2023; 15(21).

PMID: 37958354 PMC: 10650285. DOI: 10.3390/cancers15215180.

p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.

Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K Sci Rep. 2023; 13(1):16017.

PMID: 37749105 PMC: 10520030. DOI: 10.1038/s41598-023-40612-9.

Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study.

Ieni A, Pizzimenti C, Broggi G, Caltabiano R, Germano A, Barbagallo G Oncol Lett. 2022; 24(4):336.

PMID: 36039055 PMC: 9404704. DOI: 10.3892/ol.2022.13456.

Ophthalmoplegia in a Her2+ and β-hCG+ Patient With Leptomeningeal Carcinomatosis Secondary to Gastric Adenocarcinoma.

Falk Z, Bou Nasif M, Fallouh N Cureus. 2022; 14(7):e26658.

PMID: 35815304 PMC: 9266915. DOI: 10.7759/cureus.26658.

Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.

Tsujio G, Maruo K, Yamamoto Y, Sera T, Sugimoto A, Kasashima H BMC Cancer. 2022; 22(1):598.

PMID: 35650563 PMC: 9161565. DOI: 10.1186/s12885-022-09681-3.

References

Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V . The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol. 2013; 44(9):1804-10. DOI: 10.1016/j.humpath.2013.01.023. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Kim M, Lee H, Yang H, Bang Y, Kim W . Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011; 59(5):822-31. PMC: 3267049. DOI: 10.1111/j.1365-2559.2011.04012.x. View

Merrick D, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith R . Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res. 2006; 12(7 Pt 1):2281-8. DOI: 10.1158/1078-0432.CCR-05-2291. View

Uguen A . About HER2 monitoring using liquid biopsies in patients with gastric cancer. Gastric Cancer. 2017; 20(6):1011-1012. DOI: 10.1007/s10120-017-0715-8. View

Crane S, Richard Locke 3rd G, Harmsen W, Diehl N, Zinsmeister A, Melton 3rd L . The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther. 2007; 25(4):447-53. DOI: 10.1111/j.1365-2036.2006.03229.x. View

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

Ruggeri R, Campenni A, Giuffre G, Giovanella L, Siracusa M, Simone A . HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin. Int J Mol Sci. 2016; 17(12). PMC: 5187840. DOI: 10.3390/ijms17122040. View

Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo G, Plebani M . Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011; 17(41):4596-601. PMC: 3225096. DOI: 10.3748/wjg.v17.i41.4596. View

10.

Hicks D, Whitney-Miller C . HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol. 2011; 19(6):506-8. DOI: 10.1097/PAI.0b013e31822c3a0f. View

11.

Press M, Villalobos I, Santiago A, Guzman R, Cervantes M, Gasparyan A . Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. Arch Pathol Lab Med. 2016; 140(11):1250-1258. PMC: 9022709. DOI: 10.5858/arpa.2016-0009-OA. View

12.

Gerson J, Skariah S, Denlinger C, Astsaturov I . Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs. 2017; 26(5):531-540. PMC: 5563845. DOI: 10.1080/13543784.2017.1315406. View

13.

Van Bockstal M, Lambein K, Denys H, Braems G, Nuyts A, Van den Broecke R . Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype. Virchows Arch. 2014; 465(3):275-89. DOI: 10.1007/s00428-014-1609-3. View

14.

Kim M, Jung E, Lee H, Lee H, Jeon Y, Yang H . Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007; 38(9):1386-93. DOI: 10.1016/j.humpath.2007.02.005. View

15.

Vakiani E . HER2 testing in gastric and gastroesophageal adenocarcinomas. Adv Anat Pathol. 2015; 22(3):194-201. DOI: 10.1097/PAP.0000000000000067. View

16.

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

17.

Matsuno K, Ishihara R, Ohmori M, Iwagami H, Shichijyo S, Maekawa A . Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. J Gastroenterol. 2019; 54(9):784-791. DOI: 10.1007/s00535-019-01577-7. View

18.

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M . Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2018; 22(3):518-525. PMC: 6476840. DOI: 10.1007/s10120-018-0887-x. View

19.

Rugge M, Genta R . Staging and grading of chronic gastritis. Hum Pathol. 2005; 36(3):228-33. DOI: 10.1016/j.humpath.2004.12.008. View

20.

Qiu M, Shi S, Chen M, Wang J, Wu Q, Sheng H . Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer. J Cancer. 2017; 8(17):3531-3537. PMC: 5687168. DOI: 10.7150/jca.19984. View